Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 145
Filter
Add more filters










Publication year range
1.
Br J Dermatol ; 164(4): 720-8, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21155750

ABSTRACT

BACKGROUND: Melanoma is often infiltrated by inflammatory and immune cells that might either maintain chronic inflammation, therefore promoting tumour growth, or mount an antitumour response to control tumour outcome. In this setting, Th1-oriented lymphocyte infiltration is associated with a better outcome in melanoma. Although the interferon-induced protein CXCL10 is expressed by Th1 immune cells, its receptor was also shown to be involved in melanoma progression and metastasis. OBJECTIVES: To investigate the CXCL10-mediated antitumoral response in vivo, and its clinical relevance. Methods C57BL/6 mice bearing B16F1 melanoma were treated intraperitoneally with an adenovirus vector expressing CXCL10. In addition, peripheral blood mononuclear cells (PBMC) from 20 patients, 10 with melanoma in remission and 10 with melanoma in progression, were assessed for their cytokine/chemokine content using a 30-plex assay, and for their ability to modulate melanoma invasion in vitro in Transwell(®) (Sigma-Aldrich) chambers coated with Matrigel(®) (BD Biosciences). RESULTS: Treatment with CXCL10 reduced melanoma tumour growth in C57BL/6 mice compared with controls in vivo, and reduced melanoma invasion in vitro. Screening for expression of 30 cytokine/chemokine proteins showed that only CXCL10 was significantly increased in patients in remission compared with patients in progression. PBMC only from patients in remission significantly reduced melanoma cell invasiveness in an ex vivo Transwell(®) assay. Accordingly, this inhibitory effect was also observed with PBMC culture media from patients with melanoma in remission. CONCLUSIONS: The quantitative increase in CXCL10 production, together with its ability to limit melanoma progression, shows the potential benefit of this chemokine to control melanoma progression or metastasis.


Subject(s)
Chemokine CXCL10/physiology , Melanoma/pathology , Melanoma/therapy , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Adult , Aged , Animals , Blotting, Western , Cell Proliferation/drug effects , Chemokine CXCL10/therapeutic use , Chemokines/metabolism , Cytokines/metabolism , Disease Models, Animal , Female , Humans , Injections, Intraperitoneal , Leukocytes, Mononuclear/physiology , Male , Melanoma/metabolism , Mice , Mice, Inbred C57BL , Middle Aged , Neoplasm Invasiveness/physiopathology , Skin Neoplasms/metabolism , Tumor Cells, Cultured
2.
Int J Biochem Cell Biol ; 40(8): 1581-96, 2008.
Article in English | MEDLINE | ID: mdl-18206415

ABSTRACT

Membrane-type I matrix metalloproteinase (MT1-MMP) has been previously reported to be up-regulated in human microvascular endothelial cell-1 line (HMEC) by elastin-derived peptides (elastokines). The aim of the present study was to identify the signaling pathways responsible for this effect. We showed that elastokines such as (VGVAPG)(3) peptide and kappa elastin induced nitric oxide (NO) production in a time-, concentration- and receptor-dependent manner as it could be abolished by lactose and a receptor-derived competitive peptide. As evidenced by the use of NO synthase inhibitors, elastokine-mediated up-regulation of MT1-MMP and pseudotube formation on Matrigel required NO production through activation of the PI(3)-kinase/Akt/NO synthase and NO/cGMP/Erk1/2 pathways. Elastokines induced both PI(3)-kinase p110gamma sub-unit, Akt and Erk1/2 activation, as shown by a transient increase in phospho-Akt and phospho-Erk1/2, reaching a maximum after 5 and 15 min incubation, respectively. Inhibitors of PI(3)-kinase and MEK1/2 suppressed elastokine-mediated MT1-MMP expression at both the mRNA and protein levels, and decreased the ability of elastokines to accelerate pseudotube formation. Besides, elastokines mediated a time- and concentration-dependent increase of cGMP, suggesting a link between NO and MT1-MMP expression. This was validated by the use of a guanylyl cyclase inhibitor, a NO donor and a cGMP analog. The guanylyl cyclase inhibitor abolished the stimulatory effect of elastokines on MT1-MMP expression. Inversely, the cGMP analog, mimicked the effect of both elastokines and NO donor in a concentration- and time-dependent manner. Overall, our results demonstrated that such elastokine properties through NO and MT1-MMP may be of importance in the context of tumour progression.


Subject(s)
Elastin/pharmacology , Endothelial Cells/metabolism , Matrix Metalloproteinase 14/biosynthesis , Nitric Oxide/physiology , Oligopeptides/pharmacology , Cell Line , Chromones/pharmacology , Endothelial Cells/drug effects , Humans , Mitogen-Activated Protein Kinase 1/physiology , Mitogen-Activated Protein Kinase 3/physiology , Morpholines/pharmacology , Nitric Oxide/biosynthesis , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/physiology , Phosphatidylinositol 3-Kinases/physiology , Phosphoinositide-3 Kinase Inhibitors , Proto-Oncogene Proteins c-akt/physiology , Signal Transduction/drug effects , Up-Regulation
3.
J Dent Res ; 85(8): 745-50, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16861293

ABSTRACT

Elastin peptides were previously reported to increase MMP expression in several cell types. We found binding of these peptides to their receptors led to enhanced MMP-3 and MMP-1 expression, but not activation, in human gingival fibroblasts cultured on plastic dishes. We hypothesized that these peptides, in a more physiological environment, might additionally trigger an MMP-3/MMP-1 activation cascade, leading to matrix lysis, as occurs in periodontitis. To test this hypothesis, we used contracted and attached lattices as gingival lamina propria equivalents. In such 3D models, supplementation of elastin peptides and plasminogen triggered an MMP-3/MMP-1 activation cascade and significant down-regulation of TIMPs production, further leading to intense collagen degradation. We propose that elastolysis, as occurs in periodontitis, potentiates collagenolysis, thus promoting disease progression.


Subject(s)
Elastin/metabolism , Fibrillar Collagens/metabolism , Gingiva/metabolism , Matrix Metalloproteinase 3/metabolism , Adult , Blotting, Western , Cell Culture Techniques , Cells, Cultured , Enzyme Activation , Fibroblasts/metabolism , Gingiva/cytology , Humans , Matrix Metalloproteinase 1/metabolism , Middle Aged , Models, Biological , Oligopeptides/metabolism , Plasminogen/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tissue Inhibitor of Metalloproteinases/antagonists & inhibitors
4.
Ann Pharm Fr ; 64(2): 83-6, 2006 Mar.
Article in French | MEDLINE | ID: mdl-16568008

ABSTRACT

Expression of melanoma invasiveness, ultimately leading to the formation of metastases, requires that cancer cells break through the successive skin barriers (dermo-epidermal junction, dermis) constituted of various extracellular matrix constituents. In order to facilitate their progression, melanoma cells express, in concert with stromal cells, a group of proteolytic systems which degrade this extracellular structures. However, proteolysis of basement membrane, collagen or elastic fibers can uncover cryptic sites or/and liberate matrix fragments whose properties appeared distinct from their intact macromolecule counterparts. Those fragments, called matrikines, are able to empede or to accelerate melanoma progression ex vivo and in vivo. Non-collagenous domains of basement membrane collagens, which behave like potent "matstatins", are seen as potential pharmacological agents in melanoma.


Subject(s)
Melanoma/pathology , Peptides/physiology , Skin Neoplasms/pathology , Collagen/metabolism , Extracellular Matrix/metabolism , Extracellular Matrix/pathology , Humans , Melanoma/metabolism , Neoplasm Invasiveness , Skin/pathology , Skin Neoplasms/metabolism
5.
Pathol Biol (Paris) ; 53(7): 405-10, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16085117

ABSTRACT

Gelatinase A, a member of the matrix metalloproteinase family, contains three fibronectin type II (FnII)-like modules that are inserted within its catalytic domain. These FnII modules, defined as exosites, play an essential role in targeting the enzyme to matrix macromolecules, a process which can down-regulate membrane-type metalloproteinase-driven progelatinase A activation. The exosite/substrate-directed gelatinase inhibitors has been proposed as an alternative approach to disappointing active site-directed inhibitors, to control gelatinase A activity. In preliminary experiments, we evidenced that long-chain unsaturated fatty acids could bind preferentially to the first FnII module of gelatinase A. This interaction inhibits the activity of this enzyme towards proteins (type I gelatin and collagen) and an octapeptide substrate, with K(i) in the micromolar range. Since gelatinase A-catalyzed matrix proteolysis might display a positive or negative influence (depending on the substrate cleaved), the design of exosite-specific compounds for noncatalytic targeting of gelatinase A would necessitate an extensive degradomic analysis.


Subject(s)
Fibronectins/physiology , Matrix Metalloproteinase 2/chemistry , Matrix Metalloproteinase 2/metabolism , Amino Acid Motifs , Humans , Kinetics , Substrate Specificity , Tissue Inhibitor of Metalloproteinase-2/metabolism
6.
Biochimie ; 87(12): 1121-6, 2005 Dec.
Article in English | MEDLINE | ID: mdl-15953673

ABSTRACT

Interleukin-1 beta (IL-1beta) is an important regulator of the thyroid cell function. This cytokine has been largely described to trigger an important biological signaling cascade: the sphingomyelin/ceramide pathway. In this report, we show that IL-1beta induces the transient activation of a neutral sphingomyelinase in porcine thyroid cells. Moreover, IL-1beta and ceramides are demonstrated to inhibit the TSH-induced cAMP production via the implication of alphaGi subunit of the adenylyl cyclase system. This crosstalk between cAMP and ceramide pathways constitutes a preponderant process in the TSH-controlled differentiation state of thyrocytes. All these results argue for the involvement of ceramides and IL-1beta in the thyroid function regulation, leading to a cell dedifferentiated state.


Subject(s)
Ceramides/physiology , Cyclic AMP/physiology , Epithelial Cells/physiology , Interleukin-1/pharmacology , Signal Transduction/drug effects , Sphingomyelin Phosphodiesterase/metabolism , Thyroid Gland/cytology , Animals , Epithelial Cells/drug effects , Kinetics , Pertussis Toxin/pharmacology , Swine , Thyroid Gland/drug effects , Thyroid Gland/physiology
7.
Pathol Biol (Paris) ; 52(3): 154-9, 2004 Apr.
Article in French | MEDLINE | ID: mdl-15063935

ABSTRACT

Among skin cancers, melanoma is probably the most highly invasive and metastasizing, with a poor outcome. During melanoma progression, tumor cells must across the dermal-epidermal junction, and invade the dermis, its principal site of propagation. Therefore, degradation of matrix proteins constituting dermal-epidermal junction and dermis by proteolytic enzymes is an essential step of melanoma invasion. Serines proteinases and Matrix Metalloproteinases (MMPs) families are the main degrading substances involved in this process. Among MMPs, the expression of MMP-1, -2, -3, -9, -14, 15, -16 by melanoma cells was shown in vitro and in vivo, and correlated with the invasive phenotype. In addition to disrupt matrix proteins, MMPs can also cleave non matrix components such as cytokines, and growth factors. The modifications generated by the remodeling of matrix and non-matrix components can influence melanoma cells proliferation, adhesion, vascularization, survival, proteases expression, and migration. Thus, using inhibitors in order to control expression, activation and activity of MMPs could regulate cellular process which led to melanoma progression.


Subject(s)
Matrix Metalloproteinases/physiology , Melanoma/enzymology , Neoplasm Proteins/physiology , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Cytokines/metabolism , Disease Progression , Enzyme Activation , Extracellular Matrix Proteins/metabolism , Growth Substances/metabolism , Humans , Matrix Metalloproteinase 2/deficiency , Matrix Metalloproteinase 2/genetics , Melanoma/drug therapy , Melanoma/pathology , Melanoma, Experimental/drug therapy , Melanoma, Experimental/enzymology , Melanoma, Experimental/pathology , Mice , Mice, Knockout , Protease Inhibitors/pharmacology , Protease Inhibitors/therapeutic use , Serine Endopeptidases/physiology , Skin Neoplasms/drug therapy , Skin Neoplasms/enzymology , Skin Neoplasms/pathology , Xenograft Model Antitumor Assays
8.
J Soc Biol ; 195(2): 165-72, 2001.
Article in French | MEDLINE | ID: mdl-11723829

ABSTRACT

Soluble elastin-derived peptides from alkaline or elastase hydrolysis of insoluble elastin, as well as tropoelastin, increase matrix metalloproteinase-2 (MMP-2) production by human skin fibroblasts in culture as determined by gelatin zymography and ELISA. Such an effect is time and concentration dependent; it can be reproduced by synthetic elastin: VGVAPG, PGAIPG, and laminin: LGTIPG, hexapeptides and inhibited by lactose and is therefore elastin receptor-mediated. The steady state levels of MMP-2 mRNAs are invariant following elastin-fibroblasts interaction. Inhibition of phospholipase C (D-609), ADP-ribosylation factor (brefeldin), protein kinase C (RO-318220) and phospholipase D (1-propanol) totally abolished the elastin-mediated increase of MMP-2 production. It suggested that the post-transcriptional mechanism controlling the elastin-mediated overproduction of MMP-2 involved a cascade leading to phospholipase D activation.


Subject(s)
Elastin/pharmacology , Fibroblasts/drug effects , Matrix Metalloproteinase 2/biosynthesis , Peptide Fragments/pharmacology , ADP-Ribosylation Factors/antagonists & inhibitors , Animals , Brefeldin A/pharmacology , Bridged-Ring Compounds/pharmacology , Cattle , Dactinomycin/pharmacology , Elastin/chemistry , Electrophoresis, Polyacrylamide Gel , Enzyme Activation/drug effects , Enzyme Induction/drug effects , Enzyme Inhibitors/pharmacology , Enzyme-Linked Immunosorbent Assay , Fibroblasts/enzymology , Humans , Indoles/pharmacology , Lactose/pharmacology , Laminin/pharmacology , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 3/biosynthesis , Matrix Metalloproteinase 3/genetics , Norbornanes , Nucleic Acid Synthesis Inhibitors/pharmacology , Peptide Fragments/chemical synthesis , Phosphatidylinositol Diacylglycerol-Lyase , Phospholipase D/metabolism , Protein Kinase C/antagonists & inhibitors , Protein Processing, Post-Translational/drug effects , Signal Transduction , Skin/cytology , Thiocarbamates , Thiones/pharmacology , Tropoelastin/chemistry , Tropoelastin/pharmacology , Type C Phospholipases/antagonists & inhibitors
9.
J Invest Dermatol ; 117(5): 1091-6, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11710917

ABSTRACT

Bullous pemphigoid is a blistering disorder associated with autoantibodies directed against two components of hemidesmosomes, BP180 and BP230. Autoantibodies to the extracellular collagenous domain of BP180 are thought to play a key role in the pathogenesis of the disease. In a murine model of bullous pemphigoid, neutrophil elastase and 92 kDa gelatinase (matrix metalloproteinase 9) have been implicated in subepidermal blister formation via proteolytic degradation of BP180. In this study we sought to elucidate the contribution of these two enzymes to subepidermal blister formation by assessing the expression, localization, and activity of the two proteases in lesional skin, serum samples, and blister fluids obtained from 17 patients with bullous pemphigoid. The results indicate that (i) neutrophil elastase is found in skin biopsy specimens from bullous pemphigoid lesions and is recovered as active enzyme in blister fluids, and (ii) although proform of matrix metalloproteinase 9 is present in lesional skin, it is present only as proenzyme in blister fluids, which also contain high levels of tissue inhibitor of metalloproteinase-1. Next, the capacity of matrix metalloproteinase 9 and neutrophil elastase to degrade a recombinant protein corresponding to the extracellular collagenous domain of the BP180 was studied. Our data illustrate that (i) recombinant matrix metalloproteinase 9, neutrophil elastase, and blister fluid from bullous pemphigoid patients are all able to hydrolyze recombinant BP180; (ii) the pattern of recombinant BP180 proteolysis with blister fluid was similar to that obtained with neutrophil elastase; and (iii) recombinant BP180 degradation by blister fluid could be inhibited by chloromethylketone, a specific elastase inhibitor, but not by batimastat, a wide spectrum matrix metalloproteinase inhibitor. Our results confirm the importance of neutrophil elastase but not matrix metalloproteinase 9 in the direct cleavage of BP180 autoantigen and subepidermal blister formation in human bullous pemphigoid.


Subject(s)
Autoantigens/metabolism , Carrier Proteins , Collagen/metabolism , Cytoskeletal Proteins , Leukocyte Elastase/metabolism , Matrix Metalloproteinase 9/metabolism , Nerve Tissue Proteins , Non-Fibrillar Collagens , Pemphigoid, Bullous/metabolism , Aged , Blister/metabolism , Body Fluids/metabolism , Dystonin , Humans , Immunohistochemistry , Middle Aged , Pemphigoid, Bullous/pathology , Tissue Inhibitor of Metalloproteinase-1/metabolism , Collagen Type XVII
10.
Exp Cell Res ; 270(1): 110-8, 2001 Oct 15.
Article in English | MEDLINE | ID: mdl-11597133

ABSTRACT

During melanoma progression, migrating cells must cross human dermis, a type I collagen-rich tissue. We have show that MMP-1 and MMP-2 act in a cumulative manner in the in vitro invasion of a three-dimensional type I collagen matrix by melanoma cells. Two melanoma cell lines (M1Dor and M3Da) previously reported to secrete proMMP-2 in a direct relationship with their tumorigenic potential into nude mice were used (F. Capon et al., 1999, Clin. Exp. Metastasis 17, 463-469). The highly tumorigenic cell line (M3Da) displayed a five-fold faster migration rate in type I collagen matrix, compared to its lower tumorigenic counterpart (M1Dor). In parallel, activation of proMMP-2 was evidenced in M3Da- but not M1Dor-populated collagen lattices. Such enzyme activation was associated with a significant decrease in TIMP-2 and TIMP-1 production. Agents known to interfere with proMMP-2 activation, i.e., excess TIMP-2, furin convertase inhibitor, and alphavbeta3 blocking antibody, reduced by 30-40% the type I collagen invasive capacity of M3Da cells. By comparison, batimastat, a wide-spectrum MMP inhibitor, exhibited a more pronounced inhibitory effect (>70%). It suggested that other collagenases than MMP-2 could participate in type I collagen invasion. Collagenase-3 (MMP-13) was produced at low levels by melanoma cells whatever the cell culture conditions. In contrast, M3Da and M1Dor cells secreted collagenase-1 (MMP-1) following 48 h of culture on plastic dishes. Growing melanoma cells in type I collagen gel did not modify enzyme production, but induced proMMP-1 activation in M3Da but not M1Dor cell-populated lattices. Blocking the plasmin-mediated proMMP-1 activation by aprotinin inhibited type I collagen gel invasion by 30%. Since the combination of aprotinin and furin convertase inhibitor reduced collagen invasiveness by melanoma cells to a level comparable to that attained with batimastat, we conclude that both MMP-2 and MMP-1 are involved in such tissue invasion.


Subject(s)
Cell Movement/physiology , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 2/metabolism , Melanoma/physiopathology , Animals , Collagen , Humans , Matrix Metalloproteinases, Membrane-Associated , Metalloendopeptidases/biosynthesis , Mice , Mice, Nude , Neoplasm Invasiveness , Tissue Inhibitor of Metalloproteinase-2/biosynthesis , Tumor Cells, Cultured
11.
Atherosclerosis ; 157(1): 251-4, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11427228

ABSTRACT

Plaques from the coronary arteries of explanted hearts showed massive calcification (15-fold increase) with a loss of scleroproteins (-36%), an increase in the collagen to elastin ratio (twofold) and activation (+15%) of matrix metalloproteinase-2 (MMP-2). Plaque-free portions of the coronary artery gave results similar to those obtained with the internal mammary artery. There was a significant correlation between plaque calcification and MMP-2 activation, suggesting that the two processes may be linked.


Subject(s)
Coronary Disease/metabolism , Matrix Metalloproteinase 2/metabolism , Scleroproteins/metabolism , Adult , Aged , Calcinosis/metabolism , Coronary Disease/pathology , Coronary Vessels/metabolism , Coronary Vessels/pathology , Enzyme Activation , Extracellular Matrix/metabolism , Extracellular Matrix/pathology , Humans , Middle Aged
12.
J Biol Chem ; 276(23): 20458-65, 2001 Jun 08.
Article in English | MEDLINE | ID: mdl-11278959

ABSTRACT

The matrix metalloproteinases gelatinase A (MMP-2) and gelatinase B (MMP-9) are implicated in the physiological and pathological breakdown of several extracellular matrix proteins. In the present study, we show that long-chain fatty acids (e.g. oleic acid, elaidic acid, and cis- and trans-parinaric acids) inhibit gelatinase A as well as gelatinase B with K(i) values in the micromolar range but had only weak inhibitory effect on collagenase-1 (MMP-1), as assessed using synthetic or natural substrates. The inhibition of gelatinases depended on fatty acid chain length (with C18 > C16, C14, and C10), and the presence of unsaturations increased their inhibitory capacity on both types of gelatinase. Ex vivo experiments on human skin tissue sections have shown that micromolar concentrations of a long-chain unsaturated fatty acid (elaidic acid) protect collagen and elastin fibers against degradation by gelatinases A and B, respectively. In order to understand why gelatinases are more susceptible than collagenase-1 to inhibition by long-chain fatty acids, the possible role of the fibronectin-like domain (a domain unique to gelatinases) in binding inhibitory fatty acids was investigated. Affinity and kinetic studies with a recombinant fibronectin-like domain of gelatinase A and with a recombinant mutant of gelatinase A from which this domain had been deleted pointed to an interaction of long-chain fatty acids with the fibronectin-like domain of the protease. Surface plasmon resonance studies on the interaction of long-chain fatty acids with the three individual type II modules of the fibronectin-like domain of gelatinase A revealed that the first type II module is primarily responsible for binding these compounds.


Subject(s)
Fatty Acids, Unsaturated/pharmacology , Fibronectins/metabolism , Matrix Metalloproteinase Inhibitors , Repetitive Sequences, Amino Acid , Collagen/metabolism , Elastin/metabolism , Fatty Acids, Unsaturated/chemistry , Fibronectins/chemistry , Humans , Hydrolysis , Kinetics , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Skin/enzymology , Skin/metabolism
13.
Cytokine ; 13(3): 174-8, 2001 Feb 07.
Article in English | MEDLINE | ID: mdl-11161461

ABSTRACT

Interleukin 1 beta (IL-1beta) is often associated with thyroidal autoimmune diseases. This cytokine has been largely described to trigger an important biological signalling pathway: the sphingomyelin/ceramide pathway. In this report we show that IL-1beta induces ceramide formation and sphingomyelin degradation in porcine thyroid cells via the activation of a neutral sphingomyelinase. Among the potential targets of IL-1beta and ceramides action, we have investigated the role of an atypical protein kinase C (PKC), the PKC zeta. We show that both IL-1beta and ceramides lead to an increase of PKCzeta activity. All these results suggest an important role for ceramides and IL-1beta in regulation of thyroid function, leading to cell survival or to apoptosis.


Subject(s)
Ceramides/physiology , Interleukin-1/physiology , Signal Transduction/immunology , Thyroid Gland/immunology , Animals , Cells, Cultured , Isoenzymes/physiology , Protein Kinase C/physiology , Sphingomyelins/physiology , Swine , Thyroid Gland/cytology , Thyroid Gland/enzymology
14.
Biochem Biophys Res Commun ; 281(2): 289-94, 2001 Feb 23.
Article in English | MEDLINE | ID: mdl-11181043

ABSTRACT

Exposure of human keratinocytes to UVA radiation induced an increase in ceramide (CER) intracellular content, with a dose-dependent effect within the range of 4-9 J/cm(2). The production of CER reached a maximum 2 h after UVA irradiation. The increase of CER was proportional to the intracellular content of reactive oxygen species, was prevented by the antioxidant vitamin E, and enhanced by the prooxidant buthionine-sulfoximine, suggesting the involvement of an oxidative stress. UVA decreased both neutral and acid sphingomyelinase activities measured in vitro. A direct cleavage of sphingomyelin to CER by UVA, recently described, was not observed under our experimental conditions. We also show that, downstream of CER, UVA activated the Ser/Thr kinases ERK, JNK, and p38. Since ceramide has been shown to play a role in stress kinase activation, our results provide a possible mechanism for UVA-induced activation of stress kinases via ceramide formation. However, the actual mechanisms whereby CER is produced in cultured cells under UVA exposure remain to be specified.


Subject(s)
Ceramides/radiation effects , JNK Mitogen-Activated Protein Kinases , Ultraviolet Rays , Cell Line , Ceramides/metabolism , Dose-Response Relationship, Radiation , Enzyme Activation/radiation effects , Humans , MAP Kinase Kinase 4 , Mitogen-Activated Protein Kinase Kinases/metabolism , Mitogen-Activated Protein Kinases/metabolism , Oxidative Stress , Reactive Oxygen Species/metabolism , Sphingomyelin Phosphodiesterase/metabolism , Sphingomyelins/metabolism , p38 Mitogen-Activated Protein Kinases
15.
Biopolymers ; 58(2): 175-85, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11093116

ABSTRACT

The high temperature dielectric relaxations of purified and elastolized ligamentum nuchae elastin in the dry state have been investigated by thermally stimulated depolarization current spectrometry, with an equivalent frequency comprised between 10(-2) and 10(-3) Hz. A main relaxation mode, located close to 150 degrees C and attributed to the dielectric manifestation of a glass transition, is found for all samples. After decomposition by the fractional polarization method, the analysis of the high temperature mode shows the existence of two relaxation mechanisms: a cooperative one, associated with flexible zones of the protein, and an isoenthalpic one, corresponding to more ordered and constrained zones. The activation parameters of the two mechanisms are dependent on the extent of elastolysis and on the nature of enzyme (pancreatic elastase vs leukocyte elastase). Both enzymes influence the dielectric behavior of elastin in a similar way: the activation enthalpy maximum of the relaxing units located in the flexible zones, characteristic of the cooperative length, decreases with increasing hydrolysis. Moreover, the isoenthalpic mechanism becomes cooperative at the highest extent of elastolysis, which highlights release of constraints in ordered zones. Nevertheless, the differences found between the two enzymatic hydrolyses are characteristic of distinct sites of cleavage in the elastin network.


Subject(s)
Elastin/chemistry , Animals , Binding Sites , Cattle , Elastin/isolation & purification , Humans , In Vitro Techniques , Leukocyte Elastase , Pancreatic Elastase , Solubility , Swine , Thermodynamics
16.
J Biol Chem ; 276(7): 5222-7, 2001 Feb 16.
Article in English | MEDLINE | ID: mdl-11084020

ABSTRACT

We have established that treatment of cultured human skin fibroblasts with tropoelastin or with heterogenic peptides, obtained after organo-alkaline or leukocyte elastase hydrolysis of insoluble elastin, induces a high expression of pro-collagenase-1 (pro-matrix metalloproteinase-1 (pro-MMP-1)). The identical effect was achieved after stimulation with a VGVAPG synthetic peptide, reflecting the elastin-derived domain known to bind to the 67-kDa elastin-binding protein. This clearly indicated involvement of this receptor in the described phenomenon. This notion was further reinforced by the fact that elastin peptides-dependent MMP-1 up-regulation has not been demonstrated in cultures preincubated with 1 mm lactose, which causes shedding of the elastin-binding protein and with pertussis toxin, which blocks the elastin-binding protein-dependent signaling pathway involving G protein, phospholipase C, and protein kinase C. Moreover, we demonstrated that diverse peptides maintaining GXXPG sequences can also induce similar cellular effects as a "principal" VGVAPG ligand of the elastin receptor. Results of our biophysical studies suggest that this peculiar consensus sequence stabilizes a type VIII beta-turn in several similar, but not identical, peptides that maintain a sufficient conformation to be recognized by the elastin receptor. We have also established that GXXPG elastin-derived peptides, in addition to pro-MMP-1, cause up-regulation of pro-matrix metalloproteinase-3 (pro-stromelysin 1). Furthermore, we found that the presence of plasmin in the culture medium activated these MMP proenzymes, leading to a consequent degradation of collagen substrate. Our results may be, therefore, relevant to pathobiology of inflammation, in which elastin-derived peptides bearing the GXXPG conformation (created after leukocyte-dependent proteolysis) bind to the elastin receptor of local fibroblasts and trigger signals leading to expression and activation of MMP-1 and MMP-3, which in turn exacerbate local connective tissue damage.


Subject(s)
Collagenases/genetics , Elastin/chemistry , Elastin/pharmacology , Enzyme Precursors/genetics , Fibroblasts/metabolism , Up-Regulation , Cells, Cultured , Circular Dichroism , Collagen/metabolism , Collagenases/biosynthesis , Collagenases/metabolism , Consensus Sequence , Enzyme Precursors/biosynthesis , Enzyme Precursors/metabolism , Humans , Matrix Metalloproteinase 1 , Metalloendopeptidases/biosynthesis , Metalloendopeptidases/genetics , Metalloendopeptidases/metabolism , Peptides/chemistry , Peptides/pharmacology , Protein Conformation , RNA, Messenger/biosynthesis , Receptors, Cell Surface/physiology
17.
Lipids ; 35(11): 1259-68, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11132185

ABSTRACT

Neutral sphingomyelinase (Smase) is a cell membrane-associated phospholipase that hydrolyzes sphingomyelin to phosphocholine and ceramide, a lipid second messenger involved in cell differentiation and/or apoptosis. We first evidenced that porcine cultured thyroid cells could express neutral Smase activity even if thyrotropin (TStH), an essential hormone in thyroid cell differentiation, was found to induce a 1.7-fold decrease in Smase activity. Triggering the ceramide pathway by exogenous addition of neutral bacterial Smase (0.1 U/mL for 48 h), which transiently increased ceramide level by fourfold, drastically modified thyroid cell morphology. The follicle-like structures generated by TSH were disrupted, and the Smase-induced cell spreading was accompanied by a parallel loss of cell ability to iodinate proteins as well as a decrease of the adenylate cyclase system response. These inhibitory effects have been reproduced using short-chain exogenous ceramide analogs (C2-ceramides). Overall these data showed that ceramides emerged as potential mediators of dedifferentiation in thyroid cells.


Subject(s)
Cell Differentiation , Ceramides/metabolism , Signal Transduction , Thyroid Gland/metabolism , Animals , Cell Differentiation/drug effects , Cells, Cultured , Sphingomyelin Phosphodiesterase/metabolism , Sphingomyelin Phosphodiesterase/pharmacology , Swine , Thyroid Gland/cytology , Thyroid Gland/drug effects , Thyroid Gland/enzymology , Thyrotropin/pharmacology
18.
Cell Growth Differ ; 11(11): 573-80, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11095246

ABSTRACT

In the present study, we demonstrate that erythropoietin (Epo) induces the expression and the release of tissue inhibitors of metalloproteinase-1 (TIMP-1) in a time- and dose-dependent manner in Epo-dependent cell line UT-7 cells and in normal human erythroid progenitor cells from cord blood (CD36+) and required de novo protein synthesis. TIMP-1 was not expressed in the absence of Epo. Inhibition of the mitogen-activated protein kinase pathway by the specific inhibitors PD98059 and U0126 and of phosphatidylinositol 3-kinase by LY294002, strongly inhibited Epo-induced TIMP-1 expression and secretion. In the absence of Epo, both latent and active forms of matrix metalloproteinase-9 (MMP-9) were secreted into media. Upon Epo stimulation, MMP-9 and pro-MMP-9 secretion was inhibited in a dose-dependent manner parallel to TIMP-1 induction. The addition of PD98059, U0126, and LY294002 in the presence of Epo restored MMP-9 production in UT-7 and CD36+ cells. Our findings strongly suggest an inversely coordinated regulation of the TIMP-1 gene and MMP-9 production by Epo via mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways.


Subject(s)
Erythropoietin/pharmacology , MAP Kinase Signaling System/drug effects , Mitogen-Activated Protein Kinases/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Tissue Inhibitor of Metalloproteinase-1/metabolism , Butadienes/pharmacology , CD36 Antigens/metabolism , Chromones/pharmacology , Cycloheximide/pharmacology , Dose-Response Relationship, Drug , Erythroid Precursor Cells/drug effects , Erythroid Precursor Cells/metabolism , Erythropoietin/antagonists & inhibitors , Flavonoids/pharmacology , Gene Expression Regulation/drug effects , Humans , MAP Kinase Kinase 1 , Matrix Metalloproteinase 9/biosynthesis , Matrix Metalloproteinase 9/metabolism , Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinase Kinases/metabolism , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Morpholines/pharmacology , Nitriles/pharmacology , Phosphoinositide-3 Kinase Inhibitors , Phosphorylation/drug effects , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein Serine-Threonine Kinases/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Tissue Inhibitor of Metalloproteinase-1/genetics , Tumor Cells, Cultured
19.
Life Sci ; 67(18): 2257-65, 2000 Sep 22.
Article in English | MEDLINE | ID: mdl-11045606

ABSTRACT

Glycyl-histidyl-lysine-Cu2+ (GHK-Cu) is a tripeptide-copper complex known to be a potent wound healing agent. We previously showed its ability to stimulate in vitro and in vivo the synthesis of extracellular matrix components. The aim of this study was to determine the effects of GHK-Cu on MMP-2 synthesis by dermal fibroblasts in culture. We showed that GHK-Cu increased MMP-2 levels in conditioned media of cultured fibroblasts. This effect was reproduced by copper ions but not by the tripeptide GHK alone. This stimulation was accompanied by an increase of MMP-2 mRNA level. We also showed that GHK-Cu increased the secretion of the tissue inhibitors of metalloproteinases, TIMP-1 and TIMP-2. Taken together, our results underline that GHK-Cu is not only an activator of connective tissue production but also of the remodeling of the extracellular matrix. It is able to modulate MMP expression by acting directly on wound fibroblasts.


Subject(s)
Growth Substances/pharmacology , Oligopeptides/pharmacology , Phosphoprotein Phosphatases/biosynthesis , Animals , Cells, Cultured , Copper/pharmacology , Dose-Response Relationship, Drug , Enzyme Precursors/biosynthesis , Fibroblasts/enzymology , Matrix Metalloproteinase 2 , Rats , Tissue Inhibitor of Metalloproteinase-1/biosynthesis , Tissue Inhibitor of Metalloproteinase-2/biosynthesis
20.
J Invest Dermatol ; 115(2): 213-8, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10951238

ABSTRACT

Primary cultures of psoriatic keratinocytes proliferated at a higher rate and produced lower amounts of matrix metalloproteinase 9 than normal keratinocytes cultured under similar conditions. Sup- plementation of psoriatic keratinocyte cell culture medium with batimastat or the use of a matrix metalloproteinase 9 blocking antibody further stimulated psoriatic keratinocyte growth. An increase in intracellular ceramide level enhanced matrix metalloproteinase 9 production and inhibited cell proliferation in parallel. Whether cells were treated with sphingomyelinase or not, however, conditioned media from psoriatic keratinocytes contained higher levels of tissue inhibitor of metalloproteinase-1 compared with matrix metalloproteinase 9 and secreted only the proenzyme form. Pro-matrix metalloproteinase 9, as well as active matrix metalloproteinase 9, was identified in membrane preparations of psoriatic keratinocytes, and enzyme amounts were greatly elevated following sphingomyelinase action. As (i) tissue inhibitor of metalloproteinase-1 antibody nearly totally abrogated keratinocyte growth and (ii) complexes of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase 9 were recovered in membrane extracts of sphingomyelinase-treated psoriatic keratinocytes, we postulate that an increased level of cell-associated matrix metalloproteinase 9 might compete for tissue inhibitor of metalloproteinase-1 binding to its receptor. As a consequence, the increased levels of matrix metalloproteinase 9 will decrease keratinocyte growth.


Subject(s)
Keratinocytes/metabolism , Keratinocytes/pathology , Matrix Metalloproteinase 9/metabolism , Psoriasis/enzymology , Psoriasis/pathology , Adult , Cell Division/physiology , Cells, Cultured , Humans , Keratinocytes/drug effects , Middle Aged , Protease Inhibitors/metabolism , Reference Values , Sphingomyelin Phosphodiesterase/pharmacology , Tissue Inhibitor of Metalloproteinase-1/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...